GlassScriptPhysician profile
Mark Cromer
NPI 1033738430
$3,989.48
in general payments reported to CMS, 2019-2025
22 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,024 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.32 | 2024-2025 | |
| Janssen Biotech, INC. | $579.36 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $544.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $374.93 | 2025 | |
| Erbe USA INC | $268.75 | 2024-2025 | Vio3, Vio3 Apc3 |
| Takeda Pharmaceuticals U.S.A., INC. | $236.72 | 2024-2025 | Entyvio, Livtencity, Eohilia |
| Janssen Scientific Affairs, LLC | $202.43 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $163.97 | 2025 | Dupixent |
| Ardelyx, INC. | $161.24 | 2024-2025 | Ibsrela |
| Olympus America INC. | $120.26 | 2025 | Single Use Repositionable Clip |
| Lilly USA, LLC | $114.01 | 2025 | Omvoh |
| Terumo Medical Corporation | $107.24 | 2025 | Azur Cx Detachable, Hydropearl, Progreat |
| Aimmune Therapeutics, INC. | $48.48 | 2025 | Zenpep, Vowst |
| Medtronic, INC. | $46.88 | 2024 | Endoflip |
| Intercept Pharmaceuticals, INC. | $46.35 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.63 | 2024-2025 | |
| Boston Scientific Corporation | $27.07 | 2025 | Apollo Esg Nxt System |
| Mirum Pharmaceuticals, INC. | $24.72 | 2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $23.90 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $23.30 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.61 | 2025 | Xifaxan |
| Organon LLC | $4.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cromer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.